(Poly)phenolic compounds and gut microbiome: new opportunities for personalized nutrition

Abstract

For decades, (poly)phenols have been linked to cardiometabolic health, but population heterogeneity limits their apparent efficacy and the development of tailored, practical protocols in dietary interventions. This heterogeneity is likely determined by the existence of different metabotypes, sub-populations of individuals metabolizing some classes of (poly)phenols differently. The gut microbiota plays a major role in this process. The impact of microbiota-related phenolic metabotypes on cardiometabolic health is becoming evident, although the picture is still incomplete, and data are absent for some classes of (poly)phenols. The lack of a complete understanding of the main microbial actors involved in the process complicates the picture. Elucidation of the mechanisms behind phenolic metabotypes requires novel experimental designs that can dissect the inter-individual variability. This paper, in addition to providing an overview on the current state-of-the-art, proposes wider metabotyping approaches as a means of paving the way towards effective personalized nutrition with dietary (poly)phenols.

Keywords

(Poly)phenol / cardiometabolic health / metabotype / gut microbiota / personalized nutrition

References

[1] Kirk EP.Pathogenesis and pathophysiology of the cardiometabolic syndrome.J Clin Hypertens (Greenwich)2009;11:761-5 PMCID:PMC2859214

[2] Mozaffarian D,Go AS.Writing Group MembersAmerican Heart Association Statistics CommitteeStroke Statistics SubcommitteeHeart disease and stroke statistics-2016 update: a report from the American heart association.Circulation2016;133:e38-360

[3] Rienks J,Nöthlings U.Association of polyphenol biomarkers with cardiovascular disease and mortality risk: a systematic review and meta-analysis of observational studies.Nutrients2017;9:415 PMCID:PMC5409754

[4] Casas R,Estruch R.Nutrition and cardiovascular health.Int J Mol Sci2018;19:3988 PMCID:PMC6320919

[5] Conlon MA.The impact of diet and lifestyle on gut microbiota and human health.Nutrients2014;7:17-44 PMCID:PMC4303825

[6] Liu RH.Health-promoting components of fruits and vegetables in the diet.Adv Nutr2013;4:384S-92S PMCID:PMC3650511

[7] Bondonno NP,Kyrø C.Flavonoid intake is associated with lower mortality in the Danish diet cancer and health cohort.Nat Commun2019;10:3651 PMCID:PMC6692395

[8] Rienks J,Oluwagbemigun K,Nöthlings U.Polyphenol exposure and risk of type 2 diabetes: dose-response meta-analyses and systematic review of prospective cohort studies.Am J Clin Nutr2018;108:49-61

[9] Rio D, Rodriguez-Mateos A, Spencer JP, Tognolini M, Borges G, Crozier A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases.Antioxid Redox Signal2013;18:1818-92 PMCID:PMC3619154

[10] Tresserra-Rimbau A,Medina-Remón A.PREDIMED Study InvestigatorsInverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study.Nutr Metab Cardiovasc Dis2014;24:639-47

[11] Rodriguez-Mateos A,Krueger CG.Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update.Arch Toxicol2014;88:1803-53

[12] Curtis PJ,Berends L.Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial.Am J Clin Nutr2019;109:1535-45 PMCID:PMC6537945

[13] Martínez-López S,Mateos R.Moderate consumption of a soluble green/roasted coffee rich in caffeoylquinic acids reduces cardiovascular risk markers: results from a randomized, cross-over, controlled trial in healthy and hypercholesterolemic subjects.Eur J Nutr2019;58:865-78

[14] Cassidy A.The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids.Am J Clin Nutr2017;105:10-22 PMCID:PMC5183723

[15] Gibney ER,Combet E.Factors influencing the cardiometabolic response to (poly)phenols and phytosterols: a review of the COST action POSITIVe activities.Eur J Nutr2019;58:37-47 PMCID:PMC6851211

[16] Morand C,Garcia-Conesa MT.Why interindividual variation in response to consumption of plant food bioactives matters for future personalised nutrition.Proc Nutr Soc2020;79:225-35

[17] Bohn T.Dietary factors affecting polyphenol bioavailability.Nutr Rev2014;72:429-52

[18] Aravind S, Wichienchot S, Tsao R, Ramakrishnan S, Chakkaravarthi S. Role of dietary polyphenols on gut microbiota, their metabolites and health benefits.Food Res Int2021;142:110189

[19] Espín JC,Tomás-Barberán FA.The gut microbiota: a key factor in the therapeutic effects of (poly)phenols.Biochem Pharmacol2017;139:82-93

[20] Cardona F,Tulipani S,Queipo-Ortuño MI.Benefits of polyphenols on gut microbiota and implications in human health.J Nutr Biochem2013;24:1415-22

[21] Lu F,Wang X,Liao X.Early-life polyphenol intake promotes Akkermansia growth and increase of host goblet cells in association with the potential synergistic effect of Lactobacillus.Food Res Int2021;149:110648

[22] Vallejo F,Escudero E.Concentration and solubility of flavanones in orange beverages affect their bioavailability in humans.J Agric Food Chem2010;58:6516-24

[23] Bolca S,Maervoet V.Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women.Br J Nutr2007;98:950-9

[24] Mena P,Tomatis VB.Inter-individual variability in the production of flavan-3-ol colonic metabolites: preliminary elucidation of urinary metabotypes.Eur J Nutr2019;58:1529-43

[25] Rowland IR,Sanders TA,Bowey EA.Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora.Nutr Cancer2000;36:27-32

[26] González-sarrías A,Pinto P.A systematic review and meta-analysis of the effects of flavanol-containing tea, cocoa and apple products on body composition and blood lipids: exploring the factors responsible for variability in their efficacy.Nutrients2017;9:746

[27] Setchell KD.Equol: pharmacokinetics and biological actions.J Nutr2010;140:1363S-8S PMCID:PMC2884334

[28] Turrini E,Milelli A,Fimognari C.Overview of the anticancer profile of avenanthramides from oat.Int J Mol Sci2019;20:4536 PMCID:PMC6770293

[29] Mena P,Acharjee A.Metabotypes of flavan-3-ol colonic metabolites after cranberry intake: elucidation and statistical approaches.Eur J Nutr2022;61:1299-317 PMCID:PMC8921115

[30] Everett JR,Veselkov KA,Nicholson JK.A unified conceptual framework for metabolic phenotyping in diagnosis and prognosis.Trends Pharmacol Sci2019;40:763-73

[31] Stevens Y,Grootaert C.The intestinal fate of citrus flavanones and their effects on gastrointestinal health.Nutrients2019;11:1464 PMCID:PMC6683056

[32] Tomás-Barberán FA,García-Villalba R.Urolithins, the rescue of “old” metabolites to understand a “new” concept: metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status.Mol Nutr Food Res2017;61:1500901

[33] García-Mantrana I,Romo-Vaquero M,Selma MV.Urolithin metabotypes can determine the modulation of gut microbiota in healthy individuals by tracking walnuts consumption over three days.Nutrients2019;11:2483 PMCID:PMC6835957

[34] Iglesias-Aguirre CE,Ávila-Gálvez MÁ.Main drivers of (poly)phenol effects on human health: metabolite production and/or gut microbiota-associated metabotypes?.Food Funct2021;12:10324-55

[35] Cortés-Martín A,Tomás-Barberán FA,Espín JC.Where to look into the puzzle of polyphenols and health?.Mol Nutr Food Res2020;64:e1900952

[36] Liu C,Beekmann K.Interindividual differences in human intestinal microbial conversion of (−)-epicatechin to bioactive phenolic compounds.J Agric Food Chem2020:14168-81 PMCID:PMC7716348

[37] Kutschera M,Blaut M,Isolation of catechin-converting human intestinal bacteria.J Appl Microbiol 2011;111:165-75.

[38] Takagaki A.Catabolism of (+)-catechin and (−)-epicatechin by rat intestinal microbiota.J Agric Food Chem2013;61:4927-35

[39] Sánchez-Patán F,Monagas M.Capability of lactobacillus plantarum IFPL935 to catabolize flavan-3-ol compounds and complex phenolic extracts.J Agric Food Chem2012;60:7142-51

[40] Senizza A,Mosele JI.Lignans and gut microbiota: an interplay revealing potential health implications.Molecules2020;25:5709 PMCID:PMC7731202

[41] Védrine N,Morand C.One-month exposure to soy isoflavones did not induce the ability to produce equol in postmenopausal women.Eur J Clin Nutr2006;60:1039-45

[42] Lu LJ,Grady JJ,Anderson KE.Altered kinetics and extent of urinary daidzein and genistein excretion in women during chronic soya exposure.Nutr Cancer1996;26:289-302

[43] González-Sarrías A,Romo-Vaquero M.Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: A randomized clinical trial.Mol Nutr Food Res2017;61:1600830

[44] Frankenfeld CL.Cardiometabolic risk and gut microbial phytoestrogen metabolite phenotypes.Mol Nutr Food Resp2017;61

[45] Hazim S,Schär MY.Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial.Am J Clin Nutr2016;103:694-702 PMCID:PMC4763500

[46] Usui T,Sasaki Y.Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status.Clin Endocrinol (Oxf)2013;78:365-72

[47] Hillesheim E.Metabotyping and its role in nutrition research.Nutr Res Rev2020;33:33-42

[48] Ashley EA.Towards precision medicine.Nat Rev Genet2016;17:507-22